Liu Min, Jin Lizhu, Cui Tianlei
/ ( 610041) Department of Nephrology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu 610041, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Sep 20;55(5):1309-1315. doi: 10.12182/20241360601.
To evaluate the application of percutaneous right atrial puncture and tunneled cuffed catheter insertion and the establishment of peripheral arteriovenous (AV) access in hemodialysis patients with superior vena cava occlusion (SVCO), and to provide evidence-based support for the re-establishment of vascular access in patients with limited vascular resources.
Patients with SVCO were enrolled. Then, either right neck percutaneous puncture catheterization or peripheral AV access construction was performed on the patients according to their personal preference. The patients were divided into the catheter group and the AV access group accordingly. Under the guidance of double C-arm digital subtraction angiography, a puncture was made in the right brachiocephalic vein or the stump of superior vena cava. Portal venous shunt instrument RUPS100 was then inserted through the guide wire, and the hard end of the guide wire was used to puncture the right atrium to achieve sharp recanalization of the occlusive superior vena cava. Afterwards, balloon expansion of the obstructive superior vena cava lesion and the subsequent implantation of the tunneled-cuffed catheter were performed. In AV access group, after evaluating the collateral veins by venougraphy and the peripheral vessel by ultrasound, autologous AV fistula or graft was established according to the vascular conditions of the patient and their personal preferences. The demographic information and clinical outcomes, such primary and primary assisted patency of access, were documented and the incidence of complications was monitored. With the duration of patent access defined as the survival time, Kaplan-Meier survival analysis was performed to compare the patency rates of the two groups.
A total of 45 SVCO patients were enrolled and underwent re-establishment of vascular access. Among them, 21 cases were in the catheter group and 24 cases were in the AV access group. All patients had their vascular access successfully constructed and received hemodialysis, and no relevant complications or deaths occurred during the procedure. Over the mean follow-up period of (471.22±125.94) days, the primary patency rates in the catheter group 95.2% and 85.7% at 6 and 12 months, respectively, and the primary assisted patency rates were 100% and 95.2%, respectively. The primary patency rates of the AV access group were 79.2% and 62.5% at 6 and 12 months, and the primary assisted patency rates were 95.8% and 87.5%, respectively. No significant difference was observed between the two groups. Kaplan-Meier survival analysis showed that the median survival time (defined as the duration of patent access) was 670.00 (468.99, 871.01) days in the catheter group and 450.00 (339.24, 560.76) days in the AV access group, with the catheter group outperforming the AV access group. The primary patency rate of the catheter group was better than that of the AV access group (=0.049). On the other hand, no significant difference was observed in the primary assisted patency rates of the two groups.
Long-term vascular access can be established for SVCO patients by either percutaneous catheterization through the right atrium of superior vena cava stump or the establishment of peripheral AV access. The comprehensive plan, which includes the establishment of AV access first and the subsequent catheterization, is expected to improve the total duration of long-term vascular access and prolong the overall survival of dialysis patients, which provides new ideas for re-establishing dialysis access in patients with exhausted central venous resources.
评估经皮右心房穿刺及带隧道带 cuff 导管置入术以及在患有上腔静脉阻塞(SVCO)的血液透析患者中建立外周动静脉(AV)通路的应用情况,并为血管资源有限的患者重建血管通路提供循证支持。
纳入 SVCO 患者。然后,根据患者个人意愿对其进行右颈经皮穿刺置管或外周 AV 通路构建。患者相应地分为导管组和 AV 通路组。在双 C 臂数字减影血管造影引导下,于右头臂静脉或上腔静脉残端进行穿刺。然后通过导丝插入门静脉分流器械 RUPS100,利用导丝硬端穿刺右心房以实现对上腔静脉闭塞段的锐利再通。之后,对上腔静脉阻塞病变进行球囊扩张并随后植入带隧道带 cuff 导管。在 AV 通路组中,通过静脉造影评估侧支静脉并通过超声评估外周血管后,根据患者血管情况及个人意愿建立自体 AV 内瘘或移植物。记录人口统计学信息和临床结局,如通路的初次和初次辅助通畅情况,并监测并发症发生率。将通路通畅持续时间定义为生存时间,采用 Kaplan-Meier 生存分析比较两组的通畅率。
共纳入 45 例 SVCO 患者并进行了血管通路重建。其中,导管组 21 例,AV 通路组 24 例。所有患者均成功构建血管通路并接受血液透析,术中未发生相关并发症或死亡。在平均随访期(471.22±125.94)天内,导管组 6 个月和 12 个月时的初次通畅率分别为 95.2%和 85.7%,初次辅助通畅率分别为 100%和 95.2%。AV 通路组 6 个月和 12 个月时的初次通畅率分别为 79.2%和 62.5%,初次辅助通畅率分别为 95.8%和 87.5%。两组间差异无统计学意义。Kaplan-Meier 生存分析显示,导管组的中位生存时间(定义为通路通畅持续时间)为 670.00(468.99,871.01)天,AV 通路组为 450.00(339.24,560.76)天,导管组优于 AV 通路组。导管组的初次通畅率优于 AV 通路组(P=0.049)。另一方面,两组的初次辅助通畅率差异无统计学意义。
对于 SVCO 患者,可通过经上腔静脉残端右心房的经皮置管或建立外周 AV 通路来建立长期血管通路。包括先建立 AV 通路随后进行置管的综合方案有望改善长期血管通路的总时长并延长透析患者的总体生存期,这为中心静脉资源耗竭的患者重建透析通路提供了新思路。